Aisling Capital Partners Iv, Lp - Net Worth and Insider Trading

Aisling Capital Partners Iv, Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aisling Capital Partners Iv, Lp owns 4 companies in total, including Zosano Pharma Corp (ZSANQ) , Sunesis Pharmaceuticals Inc (SNSS) , and Viracta Therapeutics Inc (VIRX) among others .

Click here to see the complete history of Aisling Capital Partners Iv, Lp’s form 4 insider trades.

Insider Ownership Summary of Aisling Capital Partners Iv, Lp

Ticker	Comapny	Transaction Date	Type of Owner
ZSANQ	Zosano Pharma Corp	2019-04-11	10 percent owner
SNSS	Sunesis Pharmaceuticals Inc	2019-07-15	10 percent owner
VIRX	Viracta Therapeutics Inc	2019-01-23	10 percent owner
		2021-06-24	10 percent owner

Aisling Capital Partners Iv, Lp Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Aisling Capital Partners Iv, Lp Ownership Network

Ownership Network List of Aisling Capital Partners Iv, Lp

No Data

Ownership Network Relation of Aisling Capital Partners Iv, Lp

Aisling Capital Partners Iv, Lp Owned Company Details

What does Zosano Pharma Corp do?

Who are the key executives at Zosano Pharma Corp?

Aisling Capital Partners Iv, Lp is the 10 percent owner of Zosano Pharma Corp. Other key executives at Zosano Pharma Corp include Chief Financial Officer Christine Matthews , director & Chief Executive Officer Steven Lo , and VP & Clinical Dev & Med Affairs Donald J Kellerman .

Zosano Pharma Corp (ZSANQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Zosano Pharma Corp (ZSANQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zosano Pharma Corp (ZSANQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Zosano Pharma Corp (ZSANQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zosano Pharma Corp Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Aisling Capital Partners Iv, Lp is the 10 percent owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks Judith A. Fox .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Aisling Capital Partners Iv, Lp is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Aisling Capital Partners Iv, Lp made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Aisling Capital Partners Iv, Lp is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Venbio Global Strategic Gp Iii, L.p. , and 10 percent owner Venbio Global Strategic Fund Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elevation Oncology Inc Insider Transactions

No Available Data

Aisling Capital Partners Iv, Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Aisling Capital Partners Iv, Lp. You might contact Aisling Capital Partners Iv, Lp via mailing address: 888 Seventh Avenue, 12th Floor, New York Ny 10106.

Discussions on Aisling Capital Partners Iv, Lp

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.